MedTrace Logo

A Pilot Study Using Placenta Derived Decidual Stromal Cells for Hemorrhagic Cystitis

NCT02172963 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2014-06-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy using placenta derived decidual stromal cell therapy for hemorrhagic cystitis after allogeneic hematopoietic cell transplantation. It is hypothesized that the decidual stromal cell therapy is safe to infuse and that they have a positive clinical effect.

Conditions

  • Hemorrhagic Cystitis

Interventions

BIOLOGICAL

Decidual Stromal Cell therapy

Intravenous injection with placenta derived Decidual Stromal Cells. 1-2x10\^6 cells/kg.

Sponsors & Collaborators

Principal Investigators

  • Olle Ringdén, MD, PhD · Karolinska Institutet

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02172963 on ClinicalTrials.gov